STOCK TITAN

Beta Bionics: T. Rowe Price reports 16.6% stake

T. Rowe Price Health Sciences Fund is identified as having a 5.4% interest, while clients or their custodians have dividend and sale-proceeds rights.

(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Beta Bionics, Inc. (BBNX) is the issuer for which T. Rowe Price Associates, Inc. reported beneficial ownership of 8,943,061 common shares, or 16.6%, as of September 30, 2026. The adviser reported sole voting power over 8,939,271 shares and sole dispositive power over 8,943,061 shares, with no shared voting or dispositive power. It expressly denied that its report should be construed as an admission that it is the beneficial owner.

T. Rowe Price Health Sciences Fund was identified as having an interest in 2,408,699 shares, or 5.4%, of the class. T. Rowe Price Associates stated that it manages the fund’s portfolio and does not serve as custodian for client assets; clients or their custodians or trustee banks have the right to receive dividends and sale proceeds.

Reported beneficial ownership 8,943,061 shares T. Rowe Price Associates; as of September 30, 2026
Reported percentage of class 16.6% T. Rowe Price Associates; as of September 30, 2026
Sole voting power 8,939,271 shares T. Rowe Price Associates; as of September 30, 2026
Fund interest 2,408,699 shares T. Rowe Price Health Sciences Fund; as of September 30, 2026
Fund interest as percentage of class 5.4% T. Rowe Price Health Sciences Fund; as of September 30, 2026
beneficial ownership financial
"Amount beneficially owned"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
sole voting power financial
"Sole power to vote or to direct the vote"
Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.
sole dispositive power financial
"Sole power to dispose or to direct the disposition"
Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.
investment adviser financial
"serves as investment adviser"
An investment adviser is a person or firm that professionally manages money and gives recommendations about buying, selling, or holding investments. Like a financial coach or guide, they have a legal duty to act in a client's best financial interest, so their advice, fees and potential conflicts can directly affect returns and risk — making their role important for investors who want informed, accountable help with portfolios.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many BBNX shares did T. Rowe Price Associates report?

T. Rowe Price Associates reported beneficial ownership of 8,943,061 BBNX common shares, or 16.6%, as of September 30, 2026. It reported sole voting power over 8,939,271 shares and sole dispositive power over 8,943,061 shares, while expressly denying that the report was an admission of beneficial ownership.

How many BBNX shares did T. Rowe Price Health Sciences Fund report an interest in?

T. Rowe Price Health Sciences Fund was identified as having an interest in 2,408,699 shares, or 5.4%, of the class as of September 30, 2026. The fund was described as holding the securities in its portfolio managed by T. Rowe Price Associates.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates





08659B102

(CUSIP Number)
09/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G



T. Rowe Price Associates, Inc.
Signature:Ellen York
Name/Title:Vice President
Date:10/07/2026

Keep reading